CDKN2A and melanoma: Similarly, the risk impact of rs36115365-C on melanoma was calculated by comparing a total of 192 p16-Leiden carriers who developed melanoma (median age 60) to 73 controls (median age 71), consisting of 62 carriers who did not develop melanoma and 11 carriers who developed PC but were older than 55 years of age (sub-cohort characteristics, Table 3).